Instrument Inactif

Autres langues 3D Signatures Inc Deutsche Boerse AG

Actions

CA88555C1077

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Telo Genomics Corp. announced that it has received CAD 0.65 million in funding	21/06
Telo Genomics' Myeloma Test Accepted as Lab Developed Test by College of American Pathologists	18/06
Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP	18/06
Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP	18/06
Telo Genomics Corp. Announces Results of Development, Validation and Implementation of its Machine Learning and Artificial Intelligence Modules, Use in its TeloView Myeloma Diagnostic Tests	12/06
Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024	12/06
Telo Genomics Corp. announced that it expects to receive CAD 0.6 million in funding	04/06
Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of Hematology	30/05
Telo Genomics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	28/05
Telo Genomics Corp. Signs Collaboration Agreement with Emery Pharma	15/05
Telo Genomics and Emery Pharma Announce Collaboration	15/05
Telo Genomics Receives Accreditation from College of American Pathologists	10/04
Telo Genomics Receives Accreditation from College of American Pathologists	10/04
Telo Genomics Corp. Receives Accreditation from College of American Pathologists	10/04
Telo Genomics' MRD Clinical Trial Expands into Multi-Center Trial; Shares up 9.5%	02/04
Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial	02/04
Telo Genomics Corp. Announces Patient Recruitment for Its Minimal Respiratory Disease Clinical Trial Has Been Initiated, with Several Patient Samples Received and Processed to Date	02/04
Telo Genomics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	27/02
Telo Genomics Corp. Initiates MRD Clinical Trial for Multiple Myeloma Patients	13/02
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients	13/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues 3D Signatures Inc Deutsche Boerse AG

Actions

CA88555C1077

Autres langues

Filtres